On April 9, 2024 Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, reported that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivator JAB-30355 in form of the abstract during the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 (the "AACR 2024") from April 5 to 10, 2024 (Press release, Jacobio Pharmaceuticals, APR 9, 2024, View Source [SID1234641955]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Andrea Wang-Gillam, Chief Medical Officer and Global Head of R&D of Jacobio Pharma, said: " The preclinical data of the two drugs are representatives of our continued efforts in developing drugs toward key oncogenic pathways. P53 Y220C is the first tumor suppressor gene to enter into clinical study and has the potential to be used in combination with chemotherapy or oncogenic protein inhibitors. As an important downstream target of the STING signaling pathway, PARP7 is expected to be used in combination with immunotherapy in the future. Jacobio is committed to developing both assets globally."
Details for the 2024 AACR (Free AACR Whitepaper) abstracts are as follows:
JAB-26766: a small-molecule, orally bioavailable PARP7 inhibitor with high potency and selectivity
Poster Presentation: April 9, 2024, 9:00 AM – 12:30 PM (GMT-7)
Session: PO.ET09.01 – DNA Reactive Agents
JAB-26766 is a potent, orally bioavailable PARP7 inhibitor with >1800-fold selectivity on PARP7 over PARP2. JAB-26766 as a single agent shows potent in vivo anti-tumor activities, which can be further enhanced through combination with STING agonist or anti-PD-1 mAb.
JAB-30355: A highly potent, orally bioavailable p53 Y220C reactivator
Poster Presentation: April 9, 2024, 1:30 PM – 5:00 PM (GMT-7)
Session: PO.ET09.09 – Novel Antitumor Agents 4
JAB-30355 is a potent and selective p53 Y220C reactivator. JAB-30355 exhibited dose-dependent anti-tumor activity, inducing tumor stasis or regression in multiple CDX and PDX models of ovarian cancer, pancreatic cancer, gastric cancer, and small cell lung cancer, with overall good tolerability. A phase I/IIa clinical trial to evaluate the safety and efficacy of JAB-30355 in patients with advanced solid tumor is ongoing in U.S.
The 2024 AACR (Free AACR Whitepaper) Annual Meeting will be held in San Diego, California, U.S. from April 5th to April 10th. For more information, please visit the official website of the AACR (Free AACR Whitepaper): View Source